Research Analysts Set Expectations for BrainsWay Q1 Earnings

BrainsWay Ltd. (NASDAQ:BWAY - Free Report) - Research analysts at HC Wainwright raised their Q1 2026 earnings estimates for BrainsWay in a report released on Tuesday, May 27th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.04 per share for the quarter, up from their previous forecast of $0.03. HC Wainwright has a "Buy" rating and a $16.00 price target on the stock. The consensus estimate for BrainsWay's current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for BrainsWay's Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.09 EPS and FY2026 earnings at $0.27 EPS.

BrainsWay (NASDAQ:BWAY - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. The firm had revenue of $11.54 million for the quarter, compared to analysts' expectations of $11.45 million.

BrainsWay Trading Down 1.2%

BWAY traded down $0.12 during trading hours on Wednesday, hitting $10.31. The company's stock had a trading volume of 21,175 shares, compared to its average volume of 68,147. The business's 50-day moving average price is $9.22 and its 200-day moving average price is $9.72. The stock has a market cap of $194.57 million, a price-to-earnings ratio of 103.11 and a beta of 1.25. BrainsWay has a 12 month low of $5.67 and a 12 month high of $11.79.

Institutional Investors Weigh In On BrainsWay

Institutional investors have recently made changes to their positions in the company. Valor Management LLC purchased a new position in shares of BrainsWay during the fourth quarter valued at $19,838,000. Phoenix Financial Ltd. lifted its position in shares of BrainsWay by 100.8% during the 4th quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company's stock valued at $4,552,000 after buying an additional 242,366 shares in the last quarter. ARK Investment Management LLC boosted its holdings in BrainsWay by 7.3% in the 1st quarter. ARK Investment Management LLC now owns 188,328 shares of the company's stock worth $1,783,000 after buying an additional 12,740 shares during the last quarter. MYDA Advisors LLC boosted its holdings in shares of BrainsWay by 100.2% during the 4th quarter. MYDA Advisors LLC now owns 120,100 shares of the company's stock worth $1,133,000 after purchasing an additional 60,100 shares during the last quarter. Finally, Two Sigma Investments LP raised its holdings in BrainsWay by 2.0% in the 4th quarter. Two Sigma Investments LP now owns 92,755 shares of the company's stock valued at $875,000 after buying an additional 1,786 shares during the period. Institutional investors own 30.11% of the company's stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.